*TO SUPPLY ACTINIUM PHARMACEUTICALS WITH AC-225 FOR COMPREHENSIVE DEVELOPMENT ACTIVITIES
*ACTINIUM PHARMACEUTICALS TO FURTHER DEVELOP ACTIMAB-A AS WELL AS ADDITIONAL EARLY AND LATE-STAGE DEVELOPMENT CANDIDATES FOR BOTH U.S. AND INTERNATIONAL CLINICAL TRIALS
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 25-MAR-202508:31:36.877 GMT